anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: In the current American Joint Committee on Cancer staging system, patients with pelvic nodal metastases are considered stage IV prostate cancer. This study aims to investigate whether men with prostate-specific membrane antigen positron emission tomography (PSMA PET)-detected pelvic node-positive prostate cancer at diagnosis have a better outcome compared to men with node-positive disease identified on conventional imaging.
METHODS: This is a retrospective cohort study comparing the outcomes of men with node-positive prostate cancer and disease confined to the pelvis, staged with conventional versus PSMA PET imaging. Men had to be treated definitively with a combination of androgen deprivation therapy and radiation treatment to the prostate and pelvic lymph nodes. Kaplan-Meier and Cox regression analysis was used to compare biochemical failure-free survival (BFFS) and overall survival (OS).
RESULTS: Seventy-six men with nodal metastases confined to the pelvis were identified. Fifty-one were detected with PSMA PET while 25 were staged with conventional imaging. PSMA PET staged patients had a lower proportion of Gleason 8-10 disease (78% vs. 96%) as well as a lower median prostate-specific antigen (11 ng/mL vs. 26 ng/mL). BFFS at 4 years was 72% with PSMA PET-detected node-positive disease vs. 38% with conventionally detected node-positive disease. Four-year OS was 93% with PSMA PET staged patients vs. 76% with conventionally staged patients. On multivariate analysis, the PSMA PET staged group was associated with improved BFFS (Adjusted HR = 3.00, 95% CI 1.43, 6.29, P = 0.004) and OS (Adjusted HR = 5.81, 95% CI 1.43, 23.7, P = 0.007).
CONCLUSION: Men with PSMA PET-detected node-positive prostate cancer confined to the pelvis have significantly better biochemical control and survival compared to those with node-positive pelvic disease identified through conventional staging.
This study has a multi- center, open- label, prospective and randomized clinical trial design. One hundred asthma patients who fill out the informed consent form are registered and randomized 1:1 into the ICT-based centralized clinical trial monitoring group (n=50) or the ambulatory follow-up group (n=50). The planned follow-up duration is 6 months. he ICT-based centralized clinical trial monitoring group is given home based spirometry and connecting system (gateway) equipped with personal identification system. Fingerprint registration is required in advance, so that it would be used for authentication before each use of spirometry. Symptom score and lung functions (FEV1, PEFR) obtained from gateway is saved, monitored, and sent out via a home-monitoring system. In the ICT-based centralized clinical trial monitoring group, feedback is sent to both patients and medical staff in the form of texts if there is a worsening of symptoms score and/or lung function.

Subjects are to make office visits after randomization at 4, (8), 12, (16, 20), and 24 weeks. (ICT group will not visit at the schedules in the brackets) Each visit requires measurement of Questionnaire (ACQ) lung functions.
PROBLEM TO BE SOLVED: To obtain the subject agent useful for treating symptoms of digestive organ, e.g. vomiturition, vomiting, anorexia, abdominal distension, epigastric discomfort, abdominal pain and heartburn and the above symptoms accompanied by administration of medicine by including domperidone in a specific state as an active ingredient and setting pH of the solution to a prescribed value. SOLUTION: This preparation for nasal drop is obtained by dissolving at least a part of domperidone 5-chloro-1-[1-[3-(2-oxo-1-benzimidazolinyl)propyl]-4- piperidyl]-2-benzimidazolinone} which is an active ingredient into a medium and setting pH of the solution to 4.8-7.0. The formulating ratio of domperidone is preferably 0.01-10 wt.% based on total weight of the preparation and water is preferable as the medium. The preparation is preferably formulated in the dosage form of liquid preparation, gel, suspension, aerosol, ointment, emulsion or cream. Hydrochloric acid, phosphoric acid, lactic acid or the like can be added as a solubilizer to the preparation.
Provided is a composition for preventing and treating a menopausal disorder containing extracts of  Dendropanax morbifera  LEV. as an active ingredient. Specifically, the extracts of  Dendropanax morbifera  LEV. exhibit a significant ER agonist activity within a cell, and exhibit a very potent ER agonist (full agonist) activity with an EC 50  value of about 100 μg/ml. Thus, the extracts of  Dendropanax morbifera  LEV. comprising a high content of plant metabolites similar to estrogen can be useful as hormone replacement therapy capable of improving various symptoms derived from a deficiency of estrogen in menopausal women.
BACKGROUND: Patients with thyroid carcinoma often undergo cervical lymph node dissection, which is associated with high rates of both transient and permanent postoperative hypoparathyroidism. The impact of near-infrared fluorescence imaging + indocyanine green (ICG) fluorescence on postoperative hypoparathyroidism rates after total thyroidectomy and central neck lymph node dissection was evaluated.
METHODS: All patients undergoing surgery between January 2019 and March 2023 were included and divided into three groups: a control group (parathyroid glands identified visually), a near-infrared fluorescence imaging alone group, and a near-infrared fluorescence imaging + ICG fluorescence group. The primary outcome was the transient and permanent postoperative hypoparathyroidism rates. Secondary outcomes were: length of surgery and number of parathyroid glands identified, inadvertently resected, and autotransplanted.
RESULTS: A total of 131 patients were included in the study (47 in the control group, 45 in the near-infrared fluorescence imaging alone group, and 39 in the near-infrared fluorescence imaging + ICG fluorescence group). The transient hypoparathyroidism rate was 48.9% in the control group, 37.8% in the near-infrared fluorescence imaging alone, and 5.1% in the near-infrared fluorescence imaging + ICG fluorescence group (P < 0.0001), while the permanent hypoparathyroidism rate was 8.5% in the control group, 2.2% in the near-infrared fluorescence imaging alone group, and 0% in the near-infrared fluorescence imaging + ICG fluorescence group (P = 0.096). The number of parathyroid glands identified was 159 of 188 in the control group, 165 of 180 in the near-infrared fluorescence imaging alone group, and 149 of 156 in the near-infrared fluorescence imaging + ICG fluorescence group (P = 0.002). Inadvertent resection of parathyroid glands occurred for 29 of 188 in the control group, 15 of 180 in the near-infrared fluorescence imaging alone group, and 7 of 156 in the near-infrared fluorescence imaging + ICG fluorescence group (P = 0.002), with subsequent parathyroid gland autotransplantation for 2 of 29 in the control group, 2 of 15 in the near-infrared fluorescence imaging alone group, and 3 of 7 in the near-infrared fluorescence imaging + ICG fluorescence group (P = 0.040). There was no difference in the median operating time between groups.
CONCLUSION: The use of near-infrared fluorescence imaging + ICG fluorescence decreased both transient and permanent hypoparathyroidism rates in patients undergoing total thyroidectomy and central neck lymph node dissection.
Amphiphilic block copolymers (BCPs) were prepared comprising a poly(ethylene oxide) block and a biodegradable polycarbonate block functionalized with disulfide groups and carboxylic acid groups. The BCPs form self-assembled micellar particles in aqueous solution that can be loaded with hydrophobic drugs for therapeutic drug delivery. The loaded particles have small particle sizes (<100 nm), narrow particle size distributions, and high drug loading capacity (up to about 50 wt %) based on total dry weight of the loaded particles. Particles loaded with DOX released the DOX in response to changes in pH and glutathione (GSH) redox chemistry. The loaded particles efficiently delivered and released DOX within tumor cells, effectively suppressing growth of the tumor cells at a similar or even lower drug concentration than free DOX. Blank particles containing no DOX did not induce cytotoxicity to cells.
Negatively biased pain memories robustly predict maladaptive pain outcomes in children. Both attention bias to pain and parental narrative style have been linked with the development of these negative biases, with previous studies indicating that how parents talk to their child about the pain might buffer the influence of children's attention bias to pain on the development of such negatively biased pain memories. This study investigated the moderating role of parental narrative style in the relation between pain-related attention and memory biases in a pediatric chronic pain sample who underwent a cold pressor task. Participants were 85 youth-parent dyads who reminisced about youth's painful event. Eye-tracking technology was used to assess youth's attention bias to pain information, whereas youth's pain-related memories were elicited 1 month later through telephone interview. Results indicated that a parental narrative style using less repetitive yes-no questions, more emotion words, and less fear words buffered the influence of high levels of youth's attention bias to pain in the development of negatively biased pain memories. Opposite effects were observed for youth with low levels of attention bias to pain. Current findings corroborate earlier results on parental reminiscing in the context of pain (memories) but stress the importance of matching narrative style with child characteristics, such as child attention bias to pain, in the development of negatively biased pain memories. Future avenues for parent-child reminiscing and clinical implications for pediatric chronic pain are discussed.
A system and method for detection and monitoring of medical conditions and physical and/or cognitive impairments are provided. In embodiments, the system of the present invention utilizes inertial measurements and, in some embodiments, imaging to quantify body movements and conditions. In embodiments, the present system incorporates one or more inertial measurement unit (IMU) sensors, a camera, computer vision, and a series of standardized body movements. In additional embodiments, the present system incorporates one or more IMU sensors and a series of standardized body movements without the use of a camera or computer vision. In embodiments, the present system creates and stores a personalized “digital twin” of a patient or subject's functional musculoskeletal capabilities. Such digital twin acts as a reference model of the patient or subject.
In line with the randomization list, nurses will be assigned to the intervention and control groups in line with the inclusion criteria. The nurses will be informed about the study and their written and verbal consent will be obtained to participate in the study. Data will be collected from the nurses in the intervention and control groups with a pre-test data collection form. The nurses in the intervention group will be given breathing exercise practice, while the patients in the control group will not be subjected to any intervention. In the research; triple breathing technique (full yogic breathing) and 4-7-8 breathing technique will be used. In the intervention group, the nurses will first be told face-to-face about the breathing practice and have them do it. Then, face-to-face practice will be done three days a week, and on the other days, an audio recording of the breathing exercise will be sent by the researcher to the nurses via WhatsApp and they will be practiced daily. Breathing exercise will continue for 30 days in the intervention group. Follow-up data will be collected from the control and intervention group on the 15th day as an interim follow-up (with Piper fatigue scale and perceived stress scale). On the 30th day, the research will be finalized by collecting the post-test data. At the end of the study, the nurses in the control group will be shown and practiced breathing exercises.
PURPOSE:A bathing agent having improved warmth keeping effects, comprising essence containing an alginate extracted from brown algae as a main component. CONSTITUTION:A bathing agent comprising essence containing an alginate extracted from brown algae (e.g. sea trumpet) as a main component. First the brown algae are dried, processed into fine powder, which is sufficiently stirred and washed with hot steam. The washed powder is blended with a carbonate and heated to elute various organic acids and inorganic salts as main components. The eluted solution is concentrated in vacuum, the concentrated solution is cooled, frozen and thawed so water is separated and removed to give a concentrated brown algae extracted solution. The extracted solution is filtered, purified and mixed with a proper amount of sodium sulfate, dyestuff, etc., to give a liquid bathing agent. A powdery bathing agent is obtained by absorbing the extracted solution in dextrin, freezing, drying and making into fine powder. The essence component containing an alginate has improved warmth keeping action.
BACKGROUND: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients.
METHODS: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26.
RESULTS: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022).
CONCLUSIONS: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.
Chronic liver disease and its complications are a significant global health burden. Changes in fungal communities (mycobiome), an integral component of the gut microbiome, are associated with and contribute to the development of liver disease. Fungal dysbiosis can induce intestinal barrier dysfunction and allow fungal products to translocate to the liver causing progression of disease. This review explores recent progress in understanding the compositional and functional diversity of gut mycobiome signatures across different liver diseases. It delves into causative connections between gut fungi and liver diseases. We emphasize the significance of fungal translocation, with a particular focus on fungal-derived metabolites and immune cells induced by fungi, as key contributors to liver disease. Furthermore, we review the potential impact of the intrahepatic mycobiome on the progression of liver diseases.
A tartar-dissolving dentrifice comprises a water-soluble diglycolate and, as polishing or cleaning agent, a condensed phosphate (i.e. a phosphate having more than one phosphorus atom in the molecule) which is sparingly soluble in water, i.e. producing less than 25 mols. of CaO, or the equivalent of any other di- or trivalent metal present in the phosphate, for every 100 mols. of diglycolate in aqueous solution, in the concentration ranges used in tooth pastes. Specified glycollates are the alkali metal and ammonium diglycollates; urea, guanidine and ethanolamine diglycollates used in proportions of 3 to 10% of the dentifrice. Specified phosphates are Maddrell's salt (water-insoluble sodium polyphosphate), calcium pyrophosphate, magnesium pyrophosphate, magnesium tetrametaphosphate, aluminium metaphosphate, zinc pyrophosphate, silicon phosphates and mixtures thereof.  Swelling agents, foaming substances, wetting agents, humectants and flavouring agents may also be present.  The dentifrice can have a pH of from 4,5 to 8 but preferably 6 to 7.  The diglycollates may be replaced in part by means of water-soluble salts of glycollic acid, malic acid or ascorbic acid.
The invention discloses lysozyme-encapsulated liposome. The lysozyme-encapsulated liposome comprises soya lecithin, cholesterol, lysozyme and a buffer. A mass ratio of soya lecithin to cholesterol is 2-5: 1. A mass ratio of soya lecithin to lysozyme is 10-50: 1. A solid-liquid ratio (mg/ml) of lysozyme to buffer is 0.1-0.6: 1. The invention also discloses a preparation method of the lysozyme-encapsulated liposome. The lysozyme-encapsulated liposome is prepared by a reverse evaporating method and is subjected to ultrasonic treatment in a water-bath ultrasonic instrument until a stable system is obtained. The preparation method substantially improves lysozyme-encapsulated liposome stability, determines lipid components and a buffer ratio by adjustment, and can effectively control liposome particle sizes and improve an entrapment rate by magnetic stirring, ultrasonic treatment and rotary evaporation processes.
Anthracyclines are the cornerstone in the treatment of numerous hematological and solid cancers. The most common side effect of anthracycline is cardiotoxicity and this may limits its use and increases the rate of mortality and morbidity. Cardiotoxicity is cumulative, dose dependent, and irreversible. Improvements in protective mechanisms against the cardiotoxicity of anthracycline are important to prevent the discontinuance of these chemotherapeutics.

Spironolactone is an aldosterone antagonist which blocks the last step of the rennin angiotensin aldosterone system (RAAS). The RAAS is one of the most effective systems in remodeling of the myocardium in post-myocardial damage. According to the RALES study, in patients with severe heart failure, 25 mg spironolactone per day in addition to the standard therapy has positive effects, particularly on cardiac fibrosis and on remodeling, and substantially reduces the risk of both morbidity and death. In the EPHESUS study, it has been shown that, after the myocardial damage due to infarction, the administration of aldosterone antagonists had positive effects on the remodeling process, left ventricular ejection fraction and primer end-points. In the present study, we tested the hypothesis that RAAS blockage with spironolactone may reduce the cardiotoxicity of anthracycline group chemotherapeutics.
FIELD: medicine. SUBSTANCE: method involves making cholecystectomy operation and intraoperative cholangiographic examination. Choledochus is drained through cystic duct stump using rolled-in catheter. Biliary duct healing treatment is carried out in postoperative period. 40 ml of 0.06% sodium hypochlorate solution prepared in advance is dropped via catheter at 50 drops per min rate. The treatment is carried out daily during 5 days until bacteriological bile characteristics regress takes place. EFFECT: enhanced effectiveness of treatment; lower microbe titer in inoculated bile samples. 1 tbl
Prospective, randomized, double-blinded, comparative study. Patients are randomized at the completion of induction phase therapy. Sample-size is 50 HIV-seronegative patients with culture-positive, drug susceptible TB in each treatment arm. The first 75 patients will be randomized 2:1 to 900 mg:600 mg rifapentine. The second 75 patients will be randomized 2:1 to 1200 mg:600 mg rifapentine. The DSMB will review tolerability and safety data on the first 21 patients enrolled (at the 900 mg and 600 mg doses) and approve proceeding to enrollment at the 1200 mg dose.
A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received alglucosidase alfa at their current stable dose (defined as dose \[between 20 mg/kg qow and 40 mg/kg weekly as per physician\] administered regularly for a minimum of 6 months immediately prior to entry in this study) IV infusion for 25 weeks in PAP. After PAP, participants received avalglucosidase alfa 40mg/kg IV infusion qow from Week 26 up to Week 371 in ETP.
* Effect on Thyroid Tests



The results of protein bound iodine and radioactive iodine uptake studies, which depend on iodine estimation, will not accurately reflect thyroid function for at least 16 days following administration of iodinated contrast agents. However, thyroid function tests which do not depend on iodine estimations (e.g., T3 resin uptake and total or free thyroxine T4 assays) are not affected.

  * ﻿Effect on Urine Tests



As reported with other contrast agents, iodixanol may produce a false-positive result for protein in the urine using urine dip tests. However, the Coomassie blue method has been shown to give accurate results for the measurement of urine protein in the presence of iodixanol. In addition, care should be used in interpreting the results of urine specific gravity measurements in the presence of high levels of iodixanol and other contrast agents in the urine. Refractometry or urine osmolality may be substituted.
Although early diagnosis and treatment improve survival, hepatocellular carcinoma (HCC) is rarely cured and recurs frequently after regional therapy or transplantation. Hepatic resection can improve 5-year recurrence-free survival by up to 25%. Micrometastases of HCC have been detected by molecular techniques in 88% of patients at the time of surgery, and probably cause postoperative recurrence. Efforts to reduce the risk of recurrence after a curative resection have been tried, including various regimens of adjuvant and neoadjuvant therapy.

In this study , an anti-angiogenic agent, PI-88, is being used as an adjuvant therapy for HCC patients after curative hepatic resection. The efficacy endpoints, including tumour non-recurrence rate, time to first recurrence and 1-year survival rate are being evaluated. Several risk factors associated with tumour recurrence are also being analysed.